Alimera Sciences (NASDAQ:ALIM) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the stock. Maxim Group reiterated a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. HC Wainwright lowered shares of Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 price objective for the company. in a research note on Tuesday, June 25th. Finally, Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th.

Alimera Sciences Stock Down 0.7 %

ALIM opened at $5.55 on Thursday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 2.51 and a current ratio of 2.62. The company has a market capitalization of $290.76 million, a PE ratio of -3.54 and a beta of 1.28. The stock’s fifty day moving average is $5.47 and its 200-day moving average is $4.19. Alimera Sciences has a one year low of $2.61 and a one year high of $5.65.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative return on equity of 53.49% and a negative net margin of 23.74%. On average, equities analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Alimera Sciences

A number of large investors have recently added to or reduced their stakes in ALIM. Renaissance Technologies LLC boosted its stake in Alimera Sciences by 3.9% during the 2nd quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock valued at $1,010,000 after purchasing an additional 6,900 shares during the period. Rhumbline Advisers acquired a new stake in Alimera Sciences in the 2nd quarter worth $113,000. Fifth Lane Capital LP bought a new position in Alimera Sciences during the first quarter valued at about $83,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Alimera Sciences during the 1st quarter worth approximately $169,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Alimera Sciences during the second quarter valued at approximately $344,000. Institutional investors own 99.83% of the company’s stock.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).